biostax jkb-122：Biostax Corp Announces the FDAs Acceptance of Three

Biostax Corp Announces the FDAs Acceptance of Three

2023年8月15日—BiostaxCorpAnnouncestheFDAsAcceptanceofThreeInvestigationalNewDrugApplications(IND)TransfersforJKB-122fortheTreatmentofNASH, ...。其他文章還包含有：「BiostaxCorpAnnouncesFDAAcceptanceofThree...」、「BiostaxCorpAnnouncestheFDAsAcceptanceofThree...」、「Biostax–TLR4JKB」、「ImmuneTherapeutics」、「JKB」、「新聞內容-BE63B4B6-39CF-4956」、「景凱(6549)合作夥伴ImmuneTherapeutics(已更名...

查看更多離開網站

Provide From Google

Biostax Corp Announces FDA Acceptance of Three ...

https://drug-dev.com

Biostax Corp Announces FDA Acceptance of Three Investigational New Drug Applications Transfers for JKB-122 for the Treatment of NASH, NAFLD, and AIH.

Provide From Google

Biostax Corp Announces the FDAs Acceptance of Three ...

https://www.biostaxcorp.com

Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of ...

Provide From Google

Biostax – TLR4 JKB

https://www.biostaxcorp.com

JKB-122 is a small molecule and a long-acting TLR4 antagonist. This drug has demonstrated in preclinical models anti-fibrotic, immuno-modulating, ...

Provide From Google

Immune Therapeutics

https://www.biostaxcorp.com

Biostax Corp. · Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, ...

Provide From Google